LYVE1 and glomerulosclerosis: Interestingly, SAR131675 treatment significantly decreased diabetes-induced increase in the expression of VEGFR-3 and VEGF-C in the whole kidneys, suggesting a suppression of lymphangiogenesis, which was supported by decreases in the expression of lymphatic endothelial markers LYVE-1 and podoplanin that were further associated with the prevention of glomerulosclerosis and tubulointerstitial fibrosis.